Surrozen – Tissue-Specific Antibodies

Craig Parker, President and CEO of Surrozen, a biotechnology company discusses how the company is discovering and developing drug candidates to selectively modulate the Wnt (Wingless/Integrated) pathway. He talks about the tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. He also shares some of the company’s key milestones for 2022. 

Craig Parker, MBA,  Chief Executive Officer

Craig Parker brings more than 25 years of science and business experience across leadership positions in both public and privately-held biopharmaceutical companies, as well as within financial organizations. Most recently, he was Senior Vice President of Corporate Development at Jazz Pharmaceuticals. He previously served as Executive Vice President of Corporate Development and Scientific Affairs at Geron Corporation, as well as Senior Vice President of Strategy and Corporate Development at Human Genome Sciences until the company’s acquisition by GlaxoSmithKline. He began his career in various positions at financial institutions on Wall Street, where he was one of the top-ranked biotechnology research analysts. Parker serves as a member of the Scientific Advisory Board of Life Sciences Institute, University of Michigan, and chairs the institute’s Leadership Council. Parker earned a bachelor’s degree in biological sciences from the University of Chicago, an M.B.A. from the University of Michigan and attended the Georgetown University School of Medicine.